Do older men with localized prostate cancer Gleason 8-10 benefit from curative therapy?

• Published in: Actas urologicas españolas Vol. 32; no. 6; pp. 589 - 593
• Main Authors: Ojea Calvo, A, López García, S, Rey Rey, J, Alonso Rodrigo, A, Rodríguez Iglesias, B, Barros Rodríguez, J M
• Format: Journal Article
• Language: Spanish
• Published: Spain 01.06.2008
• Subjects: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Retrospective Studies; Survival Rate
• ISSN: 0210-4806
• DOI: 10.1016/S0210-4806(08)73892-0

The aim is to analyse until which age a radical procedure could have an influence on life expectancy of patients with localized prostate cancer Gleason 8-10. We analyse retrospectively 80 patients with localized prostate cancer T1-2N0-XM0 Gleason 8-10. The patients were stratified in 2 groups: group A 34 patients who received hormonal treatment and group B, 46 patients submitted to radical prostatectomy. The analysed variables are: cancer mortality and cancer specific survival. Patients characteristics: median age group A 75 years (66-84) and group B 64 years (56-75) (p = 0.033): median followup group A 54 months (20-180) and group B 37 months (12-140) (p = 0.016); median Gleason group A 8 (8-10) and group B 8 (8-10) (p = 0.144); percentage T1 group A 24% and group B 41% (p = 0.096); median PSA group A 10 (4-91) and group B 12 (4-71) (p = 0.269). The cancer specific mortality from group A is 24 (71%) and in group B 3 (7%) (p = 0.000). In the first 5 years, 20 (59%) patients died from prostate cancer in the group A and 1 (2%) in the group B. The Kaplan-Meier curves and Log-Rank test show significant differences in the survival cancer specific between the 2 groups. The Cox regression shows that the possibilities of dying from prostate cancer are higher in the group of patients who did not receive treatment with curative intention. The relative risk (HR 95% IC) in group A is 6.826 (2.032-22.931). More than half of the patients with localized prostate cancer Gleason 8-10 treated in a conservative way die from cancer within the next 5 years since the diagnosis. The patients with a life expectancy greater than 5 years can benefit with a curative treatment.